The present study found that Akt, IL-6, JUN, NF-κB, cAMP, IL-2 and IL-4 are targets of BXHP for the treatment of SD, and that several BXHP compounds exert anti-inflammatory and immunoregulatory effects. This evidence concerns the gene AKT1 and Salla disease.